Shares in US drugs giant Eli Lilly & Co (NYSE:LLY) fell over 2% in pre-market deals as it cuts its earnings guidance for the 2015 year.
EPS (earnings per share) are now expected to be in the range of US$2.28 and US$2.33 on a reported basis, compared to previous expectations of US$2.40 to US$2.45.
It added that it expects revenue to range between US$20.2bn and US$20.7bn for the year against a consensus of revenue of US$21.6BN.
The firm, which has not indulged in acquisitions like some other in the big pharma space, said its late-stage pipeline included nine potential new medicines or diagnostic agents, which are either already in Phase III development or at the submission stage.
It said in a statement: "We expect multiple regulatory actions across therapeutic areas including diabetes, oncology and immunology."